Advertisement

Annals of Surgical Oncology

, Volume 25, Issue 2, pp 542–549 | Cite as

Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating 18F-FDG-PET Imaging with the ALBI Grade

  • Tomoaki Yoh
  • Satoru SeoEmail author
  • Satoshi Ogiso
  • Takayuki Kawai
  • Yukihiro Okuda
  • Takamichi Ishii
  • Kojiro Taura
  • Tatsuya Higashi
  • Yuji Nakamoto
  • Etsuro Hatano
  • Toshimi Kaido
  • Shinji Uemoto
Hepatobiliary Tumors

Abstract

Background

Existing prognostic systems were not developed using only objective variables available preoperatively, and therefore do not provide ideal prognostication for patients undergoing hepatectomy for hepatocellular carcinoma (HCC). We aimed to develop a preoperative prognostic model using objective variables involving two parameters: 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) and the albumin-bilirubin (ALBI) grade.

Methods

This study included 207 consecutive patients with solitary HCC who underwent 18F-FDG-PET prior to hepatectomy. The tumor to non-tumor maximum standardized uptake value ratio (TNR) was used as an 18F-FDG PET imaging parameter.

Results

The 5-year overall survival (OS) and disease-free survival (DFS) rates were 58.6% and 28.8%, respectively. Multivariate analysis of OS identified TNR ≥ 2 (hazard ratio [HR] 1.743, 95% confidence interval [CI] 1.114–2.648, p = 0.016) and ALBI grade 2 (HR 1.966, 95% CI 1.349–2.884, p < 0.001) as the only significant prognostic factors; tumor diameter and tumor markers were not significant. Patients were divided into low- (TNR < 2 and ALBI grade 1), intermediate- (TNR < 2 and ALBI grade 2, or TNR ≥ 2 and ALBI grade 1), and high-risk (TNR ≥ 2 and ALBI grade 2) groups, which differed significantly in terms of survival (5-year OS: 75.7, 49.6, and 27.3%, respectively, p < 0.001; 5-year DFS: 37.0, 24.9, and 13.6%, respectively, p < 0.001). Compared with other staging systems, our model had the best discriminatory ability (corrected Akaike information criteria 1054.8, p < 0.001) and homogeneity (likelihood ratio Chi square value 27.6, p < 0.001).

Conclusion

A preoperative prognostic model incorporating 18F-FDG-PET imaging with the ALBI grade may be useful for estimating the prognosis of selected patients with solitary HCC.

Notes

Disclosures

Tomoaki Yoh, Satoru Seo, Satoshi Ogiso, Takayuki Kawai, Yukihiro Okuda, Takamichi Ishii, Kojiro Taura, Tatsuya Higashi, Yuji Nakamoto, Etsuro Hatano, Toshimi Kaido, and Shinji Uemoto have no conflicts of interest to declare in relation to this article.

Funding

No financial support was received for this work.

Supplementary material

10434_2017_6262_MOESM1_ESM.docx (269 kb)
Supplementary material 1 (DOCX 270 kb)

References

  1. 1.
    Capuano G, Daniele B, Gaeta GB, Gallo C, Perrone F. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–55.Google Scholar
  2. 2.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–22.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    European Association for the Study of the Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRefGoogle Scholar
  4. 4.
    Dhir M, Melin AA, Douaiher J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 2016;263:1112–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Barone C, Koeberle D, Metselaar H, et al. Multidisciplinary approach for HCC patients: hepatology for the oncologists. Ann Oncol. 2013;24 Suppl 2:ii15–23.Google Scholar
  6. 6.
    Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome. J Hepatol. 2015;63:83–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Kim BK, Kim SU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Kinoshita A, Onoda H, Fushiya N, et al. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7:406–24.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004;40:1396–05.CrossRefPubMedGoogle Scholar
  10. 10.
    Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer. 2010;116:3006–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33:550–58.CrossRefPubMedGoogle Scholar
  12. 12.
    Wang YY, Zhong JH, Su ZY, et al. Albumin–bilirubin versus Child–Pugh score as a predictor of outcome after liver resection for hepatocellular carcinoma. Br J Surg. 2016;103:725–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Kitamura K, Hatano E, Higashi T, et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol. 2011;55:846–57.CrossRefPubMedGoogle Scholar
  14. 14.
    Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res. 2007;13:427–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Kawai T, Yasuchika K, Seo S, et al. Identification of keratin19-positive cancer stem cells associating human hepatocellular carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Clin Cancer Res. 2017;23:1450–60.CrossRefPubMedGoogle Scholar
  16. 16.
    Kojima H, Hatano E, Taura K, et al. Hepatic resection for hepatocellular carcinoma with tumor thrombus in the major portal vein. Dig Surg. 2015;32:413–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Nishio T, Taura K, Koyama Y, et al. Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma. Surgery. 2016;159:399–408.CrossRefPubMedGoogle Scholar
  18. 18.
    Kitamura K, Hatano E, Higashi T, et al. Preoperative FDG-PET predicts recurrence patterns in hepatocellular carcinoma. Ann Surg Oncol. 2012;19:156–62.CrossRefPubMedGoogle Scholar
  19. 19.
    Toyoda H, Lai PB, O’Beirne J, et al. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer. 2016;114:744–50.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kudo M, Matsui O, Izumi N, et al. JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458–68.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;40:205–13.CrossRefGoogle Scholar
  22. 22.
     Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Yamashita Y, Tsuijita E, Takeishi K, et al. Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol. 2012;19:2027–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Hong G, Suh KS, Suh SW, et al. Alpha-fetoprotein and 18F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64:852–922.CrossRefPubMedGoogle Scholar
  25. 25.
    Bruix J, Sherman M: Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRefPubMedGoogle Scholar
  26. 26.
    Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Taketomi A, Toshima T, Kitagawa D et al. Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2010;17:2740–46.CrossRefPubMedGoogle Scholar
  28. 28.
    Yang Y, Nagano H, Ota H, Morimoto O, Nakamura M, Wada H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery. 2007;141:196–202.CrossRefPubMedGoogle Scholar
  29. 29.
    Ochiai T, Ikoma H, Okamoto K, et al. Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg. 2012;36:136–143.CrossRefPubMedGoogle Scholar
  30. 30.
    Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117:4475–83.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Tomoaki Yoh
    • 1
  • Satoru Seo
    • 1
    Email author
  • Satoshi Ogiso
    • 1
  • Takayuki Kawai
    • 1
  • Yukihiro Okuda
    • 1
  • Takamichi Ishii
    • 1
  • Kojiro Taura
    • 1
  • Tatsuya Higashi
    • 2
  • Yuji Nakamoto
    • 3
  • Etsuro Hatano
    • 4
  • Toshimi Kaido
    • 1
  • Shinji Uemoto
    • 1
  1. 1.Department of Surgery, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.National Institute of Radiological SciencesNational Institutes of Quantum and Radiological Science and TechnologyChibaJapan
  3. 3.Department of Diagnostic Imaging and Nuclear MedicineKyoto UniversityKyotoJapan
  4. 4.Department of SurgeryHyogo College of MedicineNishinomiyaJapan

Personalised recommendations